{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-026316","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.708584+00:00","generated_at":"2026-05-17T08:39:39.156013+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kairos Pharma to present initial Phase 1 data for ENV105 in NSCLC at World Lung Cancer Conference","bullets":["Dr. Karen Reckamp to present combination of ENV105 (carotuximab) with osimertinib for advanced EGFR-mutated NSCLC.","Presentation at World Lung Cancer Conference in Barcelona, Spain, September 6-9, 2025.","Primary objective of open-label Phase 1 trial is to evaluate safety and tolerability of the combination.","ENV105 targets CD105 to reverse drug resistance; also in Phase 2 for castrate-resistant prostate cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-026316","json":"https://secwatch.observer/filing/0001641172-25-026316.json","markdown":"https://secwatch.observer/filing/0001641172-25-026316.md","text":"https://secwatch.observer/filing/0001641172-25-026316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225026316/0001641172-25-026316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225026316/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:39:39.156013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}